We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Incidence
- Degrees of severity
- Hemophilia knowledge and severity
- Types of bleeds
- Joint bleeding
- Muscle bleeding
- Soft tissue bleeding
- Life threatening bleeding
- Hemophilic arthropathy
- Hemophilic arthropathy: associated conditions
- Bleed rates/treatment
- Acceptable?
- Joint health
- Pain
- Impact on education and work
- Quality of life
- Prophylaxis
- Treatment and access considerations
- Rational for prophylaxis in moderate and mild hemophilia
- Individualized prophylaxis therapy
- New treatment paradigms
- Non-replacement therapies and gene therapies
- Case studies
- Choice: EHL factor replacement prophylaxis once every 2 weeks
- First choice: non-replacement therapies
- First choice: EHL FVIII - intermittent prophylaxis
- First choice: EHL/super EHL
- First choice: antifibrinolytics, weekly EHL and 2/week during periods
- First choice: I have no idea
- Conclusions
- Thank you
Topics Covered
- Non-severe hemophilia
- Types of bleeds in hemophilia
- Hemophilic arthropathy
- Bleed rates and treatments
- Joint disease
- Impact of hemophilia on lifestyle
- Prophylaxis
- Case studies to treat non-severe hemophilia
Talk Citation
Krassova, S. (2024, April 30). Factor VIII levels in non-severe hemophilia A [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 6, 2024, from https://doi.org/10.69645/EHTH3672.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Snejana Krassova previously worked at Bayer, Novo Nordisk and Biogen Idec.
Factor VIII levels in non-severe hemophilia A
Published on April 30, 2024
31 min
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is
Snejana Krassova.
I'm a medical doctor specializing
in immunohematology and
working in the
pharmaceutical industry
with over 20 years
of experience,
15 of them being in hemophilia.
I'm presenting today
Factor VIII levels
in non-severe hemophilia.
I believe it's a very
pertinent and acute topic
as we dealing over
the years with
severe hemophilia.
Let's discuss a little bit
more about non-severe
hemophilia.
0:33
Hemophilia is a congenital
bleeding disorder characterized
by lack of factor VIII or
factor IX coagulation factors.
As we know overall,
for all hemophilias,
the incidence is about 7,500
live male births that
have been documented.
95% of the affected are males.
Females can be affected as well,
it's about 5%.
Female carriers obviously are
involved very much in this
disorder because it's
X-linked disorder and 30% of
cases are genetic mutations
that end out of blue,
there is no hereditary
pattern identified.
All races and socioeconomic
groups are equally affected.
1:22
We have devised the
degrees of severity.
Severe hemophilia is a lack of
factor VIII or
factor IX below 1%.
That brings us to mild
and moderate hemophilia.
We over the years,
lumped them together, but
they're quite different.
We'll talk about that
later in the next slides,
but moderate hemophilia is
usually considered 1-5% and
mild hemophilia is about 5%
between 5% to below
50% slightly below 50,
because normal factor VIII and
factor IX levels are
considered 50-150%.
These are arbitrary decisions
in terms of the classification.
We've been using them for years
and today we discuss
a little bit more.
I mean, how is it levels
versus actual bleeding
patterns in these conditions?
And what factor levels we
should be striving for
in all of these situations in
terms of mild and
moderate hemophilia?
Knowledge and severity,